The price of PAVmed Inc. (NASDAQ:PAVM) shares last traded on Wall Street rose 10.98% to $0.46.
Based on available information, 4 analysts follow PAVmed Inc. (NASDAQ:PAVM). The consensus rating among analysts is ‘Overweight’. As we calculate the median target price by taking the range between a high of $8.25 and a low of $1.50, we find $2.25. Given the previous closing price of $0.42, this indicates a potential upside of 435.71 percent. PAVM stock price is now -6.38% away from the 50-day moving average and -49.22% away from the 200-day moving average. The market capitalization of the company currently stands at $47.81M.
Will You Miss Out On This Growth Stock Boom?
A new megatrend in the fintech market is well underway. Mobile payments are projected to boom into a massive $12 trillion market by 2028. According to Motley Fool this growth stock could "deliver huge returns." Not only in the immediate future but also over the next decade. Especially since the man behind this company is a serial entrepreneur who has been wildly successful over the years.
And this is just one of our 5 Best Growth Stocks To Own For 2023.
Among analysts, 1 rate the stock a hold while 3 rate it a buy. Brokers who have rated the stock have averaged $3.56 as their price target over the next twelve months.
With the price target of $8, Cantor Fitzgerald recently initiated with Overweight rating for PAVmed Inc. (NASDAQ: PAVM). On November 05, 2020, Ascendiant Capital Markets recently initiated its ‘Buy’ rating on the stock quoting a target price of $5, while ‘Maxim Group’ rates the stock as ‘Buy’.
In other news, Glennon Michael J, Director bought 100,000 shares of the company’s stock on Dec 07. The stock was bought for $62,320 at an average price of $0.62. Upon completion of the transaction, the Director now directly owns 250,000 shares in the company, valued at $0.12 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Dec 06, Director Glennon Michael J bought 88,000 shares of the business’s stock. A total of $56,082 was incurred on buying the stock at an average price of $0.64. This leaves the insider owning 150,000 shares of the company worth $69000.0. Insiders disposed of 199,973 shares of company stock worth roughly $91987.58 over the past 1 year. A total of 0.30% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in PAVM stock. A new stake in PAVmed Inc. shares was purchased by BELPOINTE ASSET MANAGEMENT LLC during the first quarter worth $44,000. VIRTU FINANCIAL LLC invested $13,000 in shares of PAVM during the first quarter. In the first quarter, AMALGAMATED FINANCIAL CORP. acquired a new stake in PAVmed Inc. valued at approximately $5,000. MODERA WEALTH MANAGEMENT, LLC acquired a new stake in PAVM for approximately $5,000. CETERA INVESTMENT ADVISERS purchased a new stake in PAVM valued at around $5,000 in the second quarter. In total, there are 86 active investors with 13.70% ownership of the company’s stock.
A candlestick chart of PAVmed Inc. (NASDAQ: PAVM) showed a price of $0.4200 on Tuesday morning. During the past 12 months, PAVmed Inc. has had a low of $0.35 and a high of $2.34. The fifty day moving average price for PAVM is $0.4922 and a two-hundred day moving average price translates $0.9048 for the stock.
The latest earnings results from PAVmed Inc. (NASDAQ: PAVM) was released for Sep, 2022. According to the Medical Devices Company, earnings per share came in at -$0.29, missing analysts’ expectations of -$0.26 by -0.03. This compares to -$0.16 EPS in the same period last year. The company reported revenue of $76000.0 for the quarter, compared to $0.2 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue fell -62.0 percent. For the current quarter, analysts expect PAVM to generate $270k in revenue.
PAVmed Inc.(PAVM) Company Profile
PAVmed Inc. operates as a medical device company in the United States. The company’s lead products include CarpX, a percutaneous device to treat carpal tunnel syndrome; and EsoCheck, an esophageal cell collection device for the early detection of adenocarcinoma of the esophagus and Barrett’s Esophagus (BE); and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay. Its product pipeline also comprises EsoCure, an esophageal ablation device to treat dysplastic BE; PortIO, an implantable intraosseous vascular access device; NextFlo, a disposable infusion platform technology; Veris cancer healthcare platform and implantable intelligent vascular port combining remote monitoring and data analytics; NextVent single-use ventilators; FlexMO medical circulatory support cannulas; Veris cardiac monitors; DisappEAR resorbable pediatric ear tubes; Solys noninvasive glucose monitoring. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.
Leave a Reply